Biogen Inc to Acquire Nightstar Therapeutics PLC to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology Call Transcript
Good morning, my name is James, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Biogen Conference Call. (Operator Instructions)
I'd now like to introduce your host Matt Calistri, Vice President of Investor Relations.
Thank you, and welcome to today's webcast to discuss our proposed acquisition of Nightstar Therapeutics. Before we begin, I encourage everyone to go to the Investor's Section of biogen.com, to find the slides that will accompany the discussion related to this call. I want to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
On today's call, I am joined by our Chief Executive Officer, Michel Vounatsos; Dr. Michael Ehlers, EVP of Research and Development; and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |